Molecular mechanisms of Bcr-Abl-induced oncogenesis

Cytokines and Molecular Therapy

Volumn 2, Issue 2, 1996, Pages 251-261

  Gishizky, Mikhail L ^a  

^a SUGEN INC   (United States)

Author keywords

Adaptor proteins; Bcr abl; Chronic myelogenous leukemia; Crkl; Grb2; She; Signal transduction; Tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; HUMAN; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 0030484505     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Kurzrock R, Gutterman JU, Talpaz M, The molecular genetics of Philadelphia chromosome-positive leukemias. NEnglJMed (1988) 319: 990-8.
2. Rosenberg N, Witte ON, The viral and cellular forms of the Abelson (abl) oncogene. Adv Vims Res (1988) 35: 39-81.
3. Daley GQ, Van Etten RA, Baltimore D, Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science (1990) 247: 824-30.
4. Elefanty AG, Hariharan IK, Gory S, bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. E/WOJ(1990) 9: 1069-78.
5. Kelliher MA, McLaughlin J, Witte, ON et al, Induction of chronic myelogenous leukemia like syndrome in mice with v-abl and BCR/ABL. Proc Nail Acad Sci USA (1990) 87: 6649-53.
6. Gishizky ML, Johnson-White J, Witte ON, Efficient transplantation of BCR-ABL induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA (1993) 90: 3755-9.
7. Heisterkanmp N, Jenster G, ten Hoeve J et al, Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 344: 251-3.
8. Voncken JW, Kaartinen V, Pattenggale PK et al, BCR/ABL p210 and p 190 cause distinct leukemia in transgenic mice. Blood (1995) 86: 4603-11.
9. Stam K, Heisterkamp N, Reynolds FH et al, Evidence that the phi gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. A'lol Cell Biol (1987) 7: 1955-60.
10. Li W, Dreazen O, Kloetzer W et al, Characterization of bcr gene products in hematopoietic cells. Oncogene (1989) 4: 127-38.
11. Maru Y, Witte ON, The bcr gene encodes a novel serine-threonine kinase activity within a single exoh. Cell (1991) 67:459-68.
12. Ridley AJ, Self AJ, Kasmi F et al, rhô family GTPase activating proteins p 190, bcr and rhoGAP show distinct specificities in vitro and in vivo. EAiBO J (1993) 12: 5151-60.
13. Chuang TH, Xu X, Kaartinen V et al, Abr and Bcr are multifunctional regulators of the Rhô GTP-binding protein family. Proc Natl Acad Sci USA (1995) 92: 10282-6.
14. Van Etten RA, Jackson P, Baltimore D, The mouse type IV c-abl gene product is a nuclear protein and activation of transforming ability is associated with cytoplasmic localization. Cell (1989) 58: 669-78.
15. Mayer BJ, Baltimore D, Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. AM Cell. Biol (1994) 14: 2883-94.
16. Pendergast AM, Gishizky ML, Havlik MH et al, SH1 domain autophosphotylation of p210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol( 1993) 13: 1728-36.
17. Afar DEH, Goga A, McLaughlin J et al, Differential complementation of Bcr-Abl point mutants with cMyc. Science (1994) 264: 424-6.
18. Cortez D, Kadlec L, Pendergast AM, Structural and signaling requirements for BCR-ABL mediated transformation and inhibition of apoptosis. Mol Cell Biol (1995) 15: 5531-41.
19. Pawson T, Gish GD, SH2 and SH3 domains: from structure to function. Cell (1992) 71: 359-62.
20. Cicchette P, Mayer BJ, Thiel G et al, Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science (1992) 257: 803-6.
21. Ren R, Mayer BJ, Cicchetti P et al, Identification of a ten-amino acid proline rich SH3 binding site. Science (1993)259: 1157-61.
22. Shi Y, Alin K, Goff SP, Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev (1995) 9: 2583-97.
23. Dai Z, Pendergast AM, Abi-2, a novel SH3-containing protein, interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev (1995) 9: 2569-82.
24. Oda T, Tamura S, Matsuguchi T et al, The Sh2 domain of ABL is not requred for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia (1995) 9: 295-301.
25. Ilaria RL, Van Etten RA, The SH2 domain of p210 BCR/ABL is not required for the transformation of hematopietic factor-dependent cells. Blood (1995) 86: 3897-904.
26. Goga A, McLaughlin J, Afar DEH et al, Alternative signals to Ras for hematopoietic transformation by the BCR-ABL oncogene. Cell (1995) 82: 981-8.
27. McWhirter JR, Wang JYJ, Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol(199l) 11: 1553-65.
28. McWhirter JR, Wang JYJ, An actin-binding function contributes to tranformation by Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J (1993) 12: 1533-46.
29. Van Etten RA, Jackson PK, Baltimore D et al, The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J. Cell Biol (1994) 124: 325-40.
30. Ren R, Ye S, Baltimore D, Abi protein-tyrosine kinase selects the crk adapter as a substrate using SH3 binding sites. Genes Dev (1994) 8: 783-95.
31. Kipreos ET, Wang JYJ, Cell cycle-regulated binding of c-abl tyrosine kinase to DNA. Science (1992) 256: 382-5.
32. Lugo TG, Pendergast AM, Muller AJ et al, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247: 1079-82.
33. McLaughlin J, Chianese E, Witte ON, Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol (1989) 9: 1866-74.
34. Muller AJ, Young JC, Pendergast AM et al, BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 11: 1785-92.
35. McWhirter JR, Galasso DL, Wang JYJ, A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. EMBOJ(1993) 12: 1533-46.
36. Pendergast AM, Muller AJ, Havlik MH et al, BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell ( 1991 ) 66: 161-71.
37. Pendergast AM, Quilliam LA, Gripe CH" et al, BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell (1993) 75: 175-85.
38. Ron D, Zannini M, Levis M et al, A region of protodbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene CDC 24, and the human breakpoint cluster gene, bcr. New Biologist (1991) 3: 372-9.
39. Shaw G, The pleckstrin homology domain: an intriguing multifunctional protein module. BioEssays (1996) 18: 35-46.
40. Magolis B, Schlessinger J, Similarity of three dimensional structure of pleckstrin homology domain and the phosphotyrosine interaction domain. Cell (1996) 85: 385-7.
41. Hariharan IK, Adams JM, Gory S, bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res (1988) 3: 387-99.
42. Anderson SM, MIadenovic J, The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood (1996) 87: 238-44.
43. Karin, M, The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Client (1995) 270: 16483-6.
44. Cahill MA, Janknecht R, Nordheim A, Signalling pathways: Jack of all cascades. CHIT Biol (1996) 6: 16-9.
45. Schlessiger J, How receptor tyrosine kinases activate Ras. Trends Biochem Sci (1993) 18: 273-5.
46. Feig LA, Cooper GM, Inhibition of NIH 3T3 cell proliferation by a mutant Ras protein with preferential affinity for GDP. Mol Cell Biol (1988) 8: 3235-43.
47. Sawyers CL, McLaugghlin J, Witte ON, Genetic requirement for Ras in the transformation of fibroblasts and hematopoitic cells by the Bcr-Abl oncogene. J Exp Med (1995) 181: 307-13.
48. Darnell JE, Kerr IM, Stark GR, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracelluar signaling proteins. Science (1994) 264: 1415-21.
49. Carlesso, N, Frank DA, Griffin JD, Tyrosyl phosphonylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopietic cell lines transformed by Bcr/Abl. J Exp AM (1996) 183:811-20.
50. Shuai K, HalpernJ, ten Hoeve J et al, Constitutive activation of STATS by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 13: 247-53.
51. Wilson-Rawls J, Xie s, Liu J et al, P210 Bcr-Abl interacts with the interleukin 3 receptor be subunit and constitutively induces its tyrosine phosphorylation. Cancer Res (1996) 56: 3426-30.
52. Yu CL, Meyer DJ, Campbell GS et al, Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the src oncoprotein. Science (1995) 269: 81-3.
53. Danial NN, Pernis A, Rothman PB, Jak-STAT signaling induced by the v-abl oncogene. Science (1995) 269: 1875-8.
54. Evan GI, Littlewood TD, The role of c-myc in cell growth. Cim Opin Genet Dev (1993) 3: 44-9.
55. Sawyers CL, Callahan W, Witte ON, Myc is essential for transformation by abl oncogenes. Cell (1992) 70: 901-10.
56. Evan GI, Wyllie AH, Gilbert CS et al, Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 69: 119-28.
57. Galaktionov K, Chen X, Beach D, Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 382: 511-17.
58. Sanchez-Garcia I, Grutz G, Tumorigenic activity of the bcr-abl oncogenes is mediated by bc!2. Proc Natl AcadSci USA (1996) 92: 5287-91.
59. Yang E, Korsmeyer SJ, Molecular thanatopsis: a discourse on the bc!2 family and cell death. Blood (1996) 88: 386-401.
60. McDonnell TJ, Korsmeyer SJ, Progression from lymphoid hyperplasia to a high-grade malignant lymphoma in mice trangenic for the t(14:18). Nature (1991) 349: 6306-10.
61. Marin MC, Hsu B, Stephens LC et al, The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res (1995) 217: 240-9.
62. Bissonnette RP, Echeverri F, Mahboubi A et al, Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (1992) 359: 552-6.
63. Tauchi T, Feng GS, Shen R et al, SH2-containing phosphotyrosine phosphatase syp is a target of p210 bcr/abl tyrosine kinase J Biol Cfiem (1994) 269: 15381-7.
64. Andoniou C, Thein CB, Langdon WY, Tumor induction by activated Abl involves tyrosine phosphorylation of the product of the cbl oncogene. EA4BO J (1994) 13: 4515-23.
65. Varticovski L, Daley GQ, Jackson P et al, Activation of phosphatidylinositol-3-kinase in cells expressing abl oncogene variants. Mol Cell Biol (1991) 11: 1107-13.
66. Puil L, Liu J, Gish G et al, Bcr/Abl oncoproteins bind directly to activators of the ras signaling pathway. £MOJ(1994) 13: 764-73.
67. Tauchi T, Boswell HS, Leibowitz D et al, Coupling between p210 bcr/abl and she and Ggrb2 adaptor proteins in hematopietic cells permits growth-factor receptor-independent link to ras activation pathway. J Exp Med (1994) 179: 167-75.
68. ten Hoeve J, Kaartinen V, Fioretos T et al, Cellular interactions of crkl, an SH2-SH3 adaptor protein. Cancer Res. (1994) 54: 2563-67.
69. Lowenstein EJ, Daly RJ, Batzer AG et al, The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinases to ras signaling. Cell (1992) 70: 431-42.
70. Gishizky ML, Cortez D, Pendergast AM, Mutant forms of growth factor-binding protein-2 reverse bcr-abl-induced transformation. Proc Natl Acad Sci USA (1995) 92: 10889-93.
71. Pear W, Baltimore D, personal communication.
72. 372. Bonfini L, Migliaccio E, Pelicci G et al, Not all she's roads lead to ras. Trends Biol Sci (1996) 21: 257-61.
73. Rozakis-Adcock M, McGlade J, Mbamalu G et al, Association of the she and Grb2/sem5 SH2 containing proteins is implicated in activation of the ras pathway by tyrosine kinases. Nature (1992) 360: 689-92.
74. van der Geer P, Wiley S, Lai VKM et al, The she adaptor protein is involved in protein-protein interac-
75. 3lions downstream of protein-tyrosine kinase activation. Tyrosine Kinase Symposium, Salk Reserach Institute, San Diego, CA, 1996, Abstract 15.
76. Gishizky ML, Hollenbach P, Hill R, unpublished observation.
77. 376. Pellici G, Lanfrancone L, Grignani F et al, A novel transforming protein (she) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 70: 93-104.
78. ten Hoeve J, Arlinghaus RB, Guo JQ et al, Tyrosine phosphorylatiqn of crkl in Philadelphia+ leukemia. Blood (1994) 84: 1731-6.
79. Oda T, Heaney C, Hagopian JR et al, Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem (1994) 269: 22 925-8.
80. Nichols GL, Raines MA, Vera JC et al, Identification of crkl as the constitutively phosphorylated 39 Kda tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood (1994) 84: 2912-8.
81. ten Hoeve J, Morris C, Heisterkamp N et al, Isolation and chromosomal localization of crkl, a human crklike gène. Oncogene (1993) 8: 2469-74.
82. Mayer B, Hamaguchi M, Hanafusa H, A novel viral oncogene with structural similarity to phospholipase C. Nature (1988) 332: 272-5.
83. Sawyers C, personal communication.
84. 383. Sattler M, Salgia R, Okuda K et'al, The protooncogene product pl20cbl and the adaptor proteins crkl and c-crk link c-abl, p!90bcr/abl and p210bcr/abl to the phosphatidyIinositol-3' kinase pathway. Oncogene (1996) 12: 839-46.
85. Andoniou CE, Thien CB, Langdon WY, The two major sites of cbl tyrosine phosphorylation in abltransformed cells select the crkl SH2 domain. Oncogene (1996) 12: 1981-89.
86. de Jong R, ten Hoeve J, Heisterkamp N et al, Crkl is complexed with tyrosine-phosphorylated cbl in Phi positive leukemia. J Biol Chem (1996) 270: 21468-71.
87. Salgia R, Uemura N, Okuda K et al, Crkl links p210bcr/abl with paxillin in chronic myelogenous leukemia cells. J Biol Chem (1995) 270: 29 145-50.
88. Gordon MY, Dowding CR, Riley GP et al, Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia. Nature (1987) 328: 342-6.
89. Verfaillie CM, McCarthy JB, McGlave PB et al, Alterations in adhesive properties of chronic myelogenous leukemic cells. jf.Clin Invest (1992) 90: 1232-41.
90. Szczylik C, Skorski T, Nicolaides NC et al, Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science (1991) 253: 562-5.
91. Shore SK, Nabissa PM, Reddy EP, Ribozymemediated cleavage of the bcr/abl oncogene transcript: in vitro cleavage of RNA and in vivo loss of p210 protein kinase activity. Oncogene (1993) 8: 3175-82.
92. Snyder DS, Wu Y, Rossi JJ et al, Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 82: 600-5.
93. Skorski T, Nieborowska-Akorska M, Nicolaides NC et al, Suppression of Philadelphia l leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc NatlAcad Sci USA (1994) 91: 4504-8.
94. Anafi M, Gazit A, Zehavi A et al, Tyrphostininduced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to-differentiate. Blood (1993) 82:3524-9.
95. Buchdunger E, Zimmermann J, Mett H et al, Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 56: 100-4.
96. Drucker BJ, Tamura S, Buchdunger E et al, Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nature Med. (1996) 2: 561-6.
97. Pawson T, Protein modules and signaling networks. Nature (1995) 373: 573-80.
98. Xie Y, Pendergast AM, Hung MC, Dominantnegative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J Biol Cliein (1995) 51: 30717-24.